| Grab Sources And More: WGRX Website. WGRX Presentation. -----
And as I mentioned above, (Nasdaq: WGRX) has several potential catalysts on our radar. Check them out:
#1. WGRX Potential Catalyst - A $70Bn Market Up For Grabs As Company Launches Medical Food, Forzet™.
Wellgistics Targets $70Bn Market Breakthrough Addressing O-zempic / G-L-P-1 Muscle Loss with Forzet(TM)
G-L-P-1 agonist market expected to grow from $70Bn in 2025 to $201Bn in 2030
Proprietary Forzet formulation provides pharmacists, physicians and patients with unique solution for G-L-P-1 drugs' primary side effect
Forzet targeting preservation of muscle while on G-L-P-1 agonist therapy to facilitate continued patient adherence and muscle redevelopment following therapy discontinuation to help mitigate weight regain
TAMPA, FLORIDA / ACCESS Newswire / March 9, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics"), ..., today announced the launch of medical food Forzet™ for the dietary management of muscle loss associated with wei-ght loss therapies. Forzet is being launched initially to physicians and pharmacists who prescribe and dispense G-L-P-1 agonist drugs. Forzet's proprietary formulation has been evaluated in multiple controlled clinical studies, including in patients with Type 2 diabetes, heart failure and COPD in Europe. Forzet will initially be be made available through the Company's affiliated pharmacy and select members of the Wellgistics Pharmacy Network. Forzet is classified as a medical food intended for the dietary management of muscle loss associated with wei-ght loss therapies under physician supervision. Forzet is not an FDA-approved drug, is available over the counter and does not require a prescription.
"Forzet is indicated for the dietary management of muscle loss associated with wei-ght loss therapies," said Prashant Patel, RPh, President & Interim-CEO of Wellgistics Health. "G-L-P-1 agonist drugs such as O-zempic®, We-govy®, Moun-jaro® and others are members of the fastest growing class of drugs worldwide because of myriad benefits that result from lo-sing weight. While the benefits of the wei-ght loss associated with G-L-P-1 agonist therapy can no longer be denied, it remains the case that a significant amount of that wei-ght loss comes from loss of muscle. As such, the Company believes there may be a significant market opp. for a medical food product that distinguishes itself from dietary supplements by virtue of its extensive clinical data package in sarcopenia associated with other muscle loss-related medical conditions and -stringent cGMP manufacturing requirements."
Mr. Patel continued, "We intend to leverage Forzet's unique value proposition by recommending it as an adjunct solution for patients prescribed G-L-P-1 agonist drugs via pop-ups through our EinsteinRx hub technology at the point-of-sale in Wellgistics Pharmacy Network pharmacies. Additionally, as we build out our own telehealth customer base where we can more fully service patients through our own Wellgistics Pharmacy both in-store and online, we intend to make G-L-P-1 drug and related solutions such as Forzet a central feature of our direct-to-consumer (DTC) offering in order to drive loyalty by way of unique product offering as we begin to expand our DTC efforts."
...
Read the full article here. -----
#2. WGRX Potential Catalyst - The Company Evaluates 5 Top Block-Chain Platforms To Help Initiate Smart Contracts.
Wellgistics Health Selects Top Five Block-chain Platforms to Initiate Patent Protected PharmacyChain(TM) Smart Contracts-enabled Pharmaceutical Drug Tracking System to Support Industry-wide Serialization Mandate
...
U.S. prescription drugs market project to grow from $634Bn market to $883Bn by 2030 according to Grandview Research
Global block-chain in heal-thcare market is projected to grow from $11Bn in 2024 to $214Bn by 2030, according to Grandview Research
TAMPA, FLORIDA / ACCESS Newswire / March 5, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics"), ..., today announced that it has completed its evaluation process to select the most suitable block-chain platforms on which to build smart contracts-enabled pharmaceutical drug tracking system PharmacyChain that will further enable industry-wide serialization mandates, such as the United States' Drug Supply Chain Security Act (DSCSA[3]). The Company selected Hyperledger Fabric, Eth-er-eum/Poly-gon, Ve-Chain, Quorum/Besu and Corda (R3) as the most suitable block-chain platforms currently in use in order to initiate PharmacyChain development. The Company is seeking to complete the development work needed to establish closed-loop, HIPAA-compliant data transfers required to complete smart contracts within its own Wellgistics Pharmacy by the end of the second quarter of 2026.
"Now that we have identified what we believe are the best technologies currently available upon which to build PharmacyChain, we are beginning the development work needed to make it operational initially within our own pharmacy by the end of next quarter," said Prashant Patel, RPh, President & Interim-CEO of Wellgistics Health. "While we intend for PharmacyChain to be made available for our own pharmacy and the 6,500+ independent pharmacies within the Wellgistics Pharmacy Network later this year, we also believe that other major pharmacy industry participants may increasingly adopt similar solutions given our strong intellectual property position. We intend to build multiple PharmacyChain options on different block-chain platforms such that large manufacturers, wholesalers and pharmacies will be incentivized to work with us in order to gain access to our patented technology to help them improve their pharmaceutical supply chain management systems, delivering on our promise of building the ‘Health Data Railroad' through tokenization and smart contracts. We intend to program PharmacyChain in such a way that other key aspects of the heal-thcare ecosystem will be able to seamlessly integrate their data in order to produce a best-in-class product for all key heal-thcare stakeholders."
...
Read the full article here. -----
#3. WGRX Potential Catalyst - A Key Partnership Expansion Aims To Add Telehealth And Mental Health AI Capabilities.
Wellgistics Health to Add Telehealth & Mental Health AI Capabilities via Tollo Health Partnership Expansion
Tollo Health recently formed subsidiary TolloCare, LLC ('TolloCare') initially targeted to provide telehealth services for G-L-P-1 and Long CVD patients
TolloCare has white-labeled telehealth capabilities via a telemedicine company with over 5,000 onboarded physicians nationwide to provide synchronous and asynchronous medical services, including prescriptions, for wei-ght loss and separately will cultivate a Long CVD physician base
Tollo Health has entered into agreement to expand TolloCare capabilities via a partnership with a stealth San Francisco Bay Area startup preparing to deploy a mental health AI app with unique tools to engage with patients
TAMPA, FLORIDA / ACCESS Newswire / February 11, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX), ..., today announced that it has expanded its partnership Tollo Health, LLC ('Tollo Health'). The partnership expansion includes the addition of telehealth services being developed by TolloCare, LLC ('TolloCare'), a wholly-owned subsidiary of Tollo Health, which focuses on telemedicine, an app-based mental health AI offering, and public health information. TolloCare was initially established to focus on G-L-P-1 and Long CVD patients and will now expand its focus to be able to service Wellgistics' emerging partnership with NFL Alumni Health.
"More and more patients are interacting with their heal-thcare professionals primarily online," said Prashant Patel, RPh, President & Interim-CEO of Wellgistics Health. "As we evolve our business model from pharmaceutical distribution-only to more comprehensively service patients both through our Wellgistics Pharmacy Network and our own online pharmacy, we understand that we must meet the patients where they are and provide convenient solutions that improve their outcomes. G-L-P-1 agonist drug use is becoming more widespread as more convenient as oral formulations begin to hit the market. Given that Forzet™ distribution is ready to begin this quarter, we believe now is the right time to expand into telemedicine. Tollo Health has positioned itself as an intellectual leader in understanding essential amino acid formulations and how they interplay with mitochondrial biology. It makes sense for us to leverage their intellectual capital to help to educate physicians and pharmacists on how best to use G-L-P-1 agonist drugs together with Forzet."
...
Read the full article here. -----
#4. WGRX Potential Catalyst - Oversold Leaning Technical Indicators Could Suggest A Healthy Reversal May Be Nearing.
At 2:45PM EST Tuesday, Barchart was reporting WGRX to have multiple oversold leaning technical indicators.
These technicals could be signaling a healthy reversal is approaching in the near term.
Here's the definition of a "reversal" from Investopedia:
"A reversal is a change in the price direction of an asset. A reversal can occur to the upside or downside. Following an uptrend, a reversal would be to the downside. Following a downtrend, a reversal would be to the upside. Reversals are based on overall price direction and are not typically based on one or two periods/bars on a chart."
Here's the technicals to pay close attention to (as of 2:45PM EST Tuesday):
- 9-Day Relative Strength Index: 28.96%
- 14-Day Relative Strength Index: 28.98%
When these numbers drop down to the 30% range and lower, they can be viewed as being in oversold territory. While in this territory, they can paint the picture of a profile that is undervalued.
Keep an eye on these technicals closely. -----
#5. WGRX Potential Catalyst - A Relatively Low Float Could Create The Potential For Heightened Volatility.
According to info from the Yahoo Finance website, WGRX has a fairly low float.
The website reports this profile to have roughly 39.13Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility potential.
If the company provides positive news towards the first part of 2026, could it help provide a breakout spark when paired with this volatility potential? -----
(Nasdaq: WGRX) Recap - 5 Potential Catalysts Just Hit Our Radar
#1. A $70Bn Market Up For Grabs As Company Launches Medical Food, Forzet™.
#2. The Company Evaluates 5 Top Block-Chain Platforms To Help Initiate Smart Contracts.
#3. A Key Partnership Expansion Aims To Add Telehealth And Mental Health AI Capabilities.
#4. Oversold Leaning Technical Indicators Could Suggest A Healthy Reversal May Be Nearing.
#5. A Relatively Low Float Could Create The Potential For Heightened Volatility. -----
We're officially kicking off coverage on Wellgistics Health, Inc. (Nasdaq: WGRX).
We'll be back to you with updates soon. Keep your eyes peeled.
Sincerely, Kai Parker StockWireNews
(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)
*StockWireNews.com (“StockWireNews” or “SWN” ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 03/10/2026 and ending on 03/11/2026 to publicly disseminate information about (WGRX:US) via digital communications. Under this agreement, TD Media LLC has paid SWN Media LLC seventeen thousand five hundred USD ("Funds"). These Funds were part of the twenty five thousand USD funds that TD Media LLC received from a third party named Beyond Media Ltd. who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither SWN Media LLC, TD Media LLC and their member own shares of (WGRX:US).
Please see important disclosure information here: https://stockwirenews.com/disclosure/wgrx-5fg3p/#details | 
0 التعليقات:
إرسال تعليق